Threshold Pharmaceuticals commences TH-302 Phase 1 clinical trial in patients with advanced leukemias

Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that it has initiated a Phase 1 clinical trial of TH-302 in patients with advanced leukemias. TH-302 is a proprietary Hypoxia-Activated Prodrug (HAP) that specifically targets tumor hypoxia.

"There is an enduring unmet need for effective new treatments for patients with refractory hematological malignancies," said Dr. Deborah Thomas, M.D., Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. "There is a strong preclinical rationale to evaluate TH-302 in this patient population and we are excited to be leading this innovative clinical trial."

Source:

 Threshold Pharmaceuticals

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study highlights disparities in stroke burden across regions